1. FDA Intensifies Crackdown: 30 Warning Letters Target Telehealth Firms Over Compounded GLP-1 Drugs
The U.S. Food and Drug Administration (FDA) is escalating its enforcement campaign against the compounding of GLP-1 receptor agonist drugs, such as semaglutide and tirzepatide, which are widely used for weight loss and diabetes. In a significant move, the agency has issued a fresh batch of 30 warning letters to telehea...